Washington, July 18 (IANS) Eli Lilly’s Alzheimer’s drug has shown promise to slow down cognitive and functional decline in people who are in early stages of the disease’s progression, according to results of phase 3 trial. This comes on the heels of Eisai and Biogen’s lecanemab, known by the brand…Read More
Another Alzheimers drug shows promise to slow disease
